VKH
AKTX

Virtu KCG Holdings’s Akari Therapeutics AKTX Stock Holding History

Virtu KCG Holdings’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$57K Buy
+16
New +$127K ﹤0.01% 2554
2015
Q2 		– Sell
-4
Closed -$26K – 3287
2015
Q1 		$26K Buy
+4
New +$100K ﹤0.01% 2920

Other funds holding AKTX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 28.91% 1-Year Est. Return

Virtu KCG Holdings's AKTX Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in Akari Therapeutics (AKTX) in Q2 2017: 16 shares worth $57K. The stake represents ﹤0.01% of the portfolio and ranks #2554 among its holdings. This is a return to the name: Virtu KCG Holdings previously reported a position in AKTX as recently as Q1 2015.

Virtu KCG Holdings first reported a position in AKTX in Q1 2015 and has held it in 2 quarters since. 14 funds tracked by Wall St. Rank hold AKTX as of Q2 2017.

  • Virtu KCG Holdings held 16 shares of Akari Therapeutics worth $57K as of Q2 2017.
  • Akari Therapeutics was a new Virtu KCG Holdings position in Q2 2017.
  • Akari Therapeutics made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2554 holding.
  • Virtu KCG Holdings first reported a position in Akari Therapeutics in Q1 2015 and has held it in 2 quarters since.
  • 14 funds tracked by Wall St. Rank held Akari Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.